The CAR-T Revolution 3 Years After FDA Approval

Dec 15, 2020 from 5 p.m. - 6:30 p.m. (ET)

Speakers: Stephan A. Grupp, MD, PhDRichard Aplenc, MD, PhD, MSCE


Three years after FDA approval of the first CAR-T therapy, Dr. Grupp will review outcomes data and provide an update on advancements and new trials in the field of cancer immunotherapy for patients with relapsed acute lymphoblastic leukemia (ALL). Dr. Aplenc will review current immunotherapeutic treatment options for pediatric acute myeloid leukemia (AML).

Learning Objectives:

  1. Explain the role of CAR-T cell therapy in relapsed ALL and requirements for safe treatment
  2. Describe the importance of T cell proliferation and persistence in CAR-T cell efficacy
  3. Discuss the current immunotherapy treatment options for children with relapsed/refractory AML

Contact: Shelly Norbury, (856) 397-5588,

Register Today

ACCME Accreditation Statement: Children’s Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Approval of AMA PRA Category 1 Credit(s) for this lecture is pending. If approved, physicians can claim CME credit commensurate with the extent of their participation in the activity for free.